Substituted fused pyrroleimines and pyrazoleimines

Details Substituted fused pyrroleimines and pyrazoleimines Substituted fused pyrroleimines and pyrazoleimines

2001-09-06

2004-06-01

Ford, John M. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S406000, C514S403000, C514S402000, C514S263200, C514S397000, C514S394000, C514S385000, C514S383000, C514S381000, C514S379000, C514S378000, C514S375000, C514S374000, C514S373000, C514S372000, C514S367000, C514S365000, C514S364000, C514S363000, C514S362000, C514S361000, C514S360000, C514S359000, C514S339000, C514S323000, C514S307000, C514S306000, C514S305000, C514S298000, C514S297000, C514S290000, C514S256000, C514S252190, C514S252130, C514S252060, C514S245000, C514S241000, C514S235500, C514S228200, C514S

Reexamination Certificate

active

06743817

ABSTRACT:

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to novel fused pyrroleoximes and fused pyrazoleoximes and other such compounds, and more specifically to preferred fused pyrroleoximes and fused pyrazoleoximes that bind with high selectivity and high affinity to the benzodiazepine site of GABA
A
receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of central nervous system (CNS) diseases.
2. Description of the Related Art
The GABA
A
receptor superfamily represents one of the classes of receptors through which the major inhibitory neurotransmitter, &ggr;-aminobutyric acid, or GABA, acts. Widely, although unequally, distributed through the mammalian brain, GABA mediates many of its actions through a complex of proteins called the GABA
A
receptor, which causes alteration in chloride conductance and membrane polarization.
A number of cDNAs for GABA
A
receptor subunits have been characterized. To date at least 6&agr;, 3&bgr;, 3&ggr;, 1&egr;, 1&dgr; and 2&rgr; subunits have been identified. It is generally accepted that native GABA
A
receptors are typically composed of 2&agr;, 2&bgr;, and 1&ggr; subunits (Pritchett & Seeburg
Science
1989; 245:1389-1392 and Knight et. al.,
Recept. Channels
1998; 6:1-18). Evidence such as message distribution, genome localization and biochemical study results suggest that the major naturally occurring receptor combinations are &agr;
1
&bgr;
2
&ggr;
2
, &agr;
2
&bgr;
3
&ggr;
2
, &agr;
3
&bgr;
3
&ggr;
2
, and &agr;
5
&bgr;
3
&ggr;
2
(Mohler et. al.,
Neuroch. Res
. 1995; 20(5): 631-636).
Benzodiazepines exert their pharmacological actions by interacting with the benzodiazepine binding sites associated with the GABA
A
receptor. In addition to the benzodiazepine site, the GABA
A
receptor contains sites of interaction for several other classes of drugs. These include a steroid binding site, a picrotoxin site, and the barbiturate site. The benzodiazepine site of the GABA
A
receptor is a distinct site on the receptor complex that does not overlap with the site of interaction for GABA or for other classes of drugs that bind to the receptor (see, e.g., Cooper, et al., The Biochemical Basis of Neuropharmacology, 6
th
ed., 1991, pp. 145-148, Oxford University Press, New York). Early electrophysiological studies indicated that a major action of the benzodiazepines was enhancement of GABAergic inhibition. Compounds that selectively bind to the benzodiazepine site and enhance the ability of GABA to open GABA
A
receptor channels are agonists of GABA receptors. Other compounds that interact with the same site but negatively modulate the action of GABA are called inverse agonists. Compounds belonging to a third class bind selectively to the benzodiazepine site and yet have little or no effect on GABA activity, but can block the action of GABA
A
receptor agonists or inverse agonists that act at this site. These compounds are referred to as antagonists.
The important allosteric modulatory effects of drugs acting at the benzodiazepine site were recognized early and the distribution of activities at different receptor subtypes has been an area of intense pharmacological discovery. Agonists that act at the benzodiazepine site are known to exhibit anxiolytic, sedative, and hypnotic effects, while compounds that act as inverse agonists at this site elicit anxiogenic, cognition enhancing, and proconvulsant effects. While benzodiazepines have a long history of pharmaceutical use as anxiolytics, these compounds often exhibit a number of unwanted side effects. These may include cognitive impairment, sedation, ataxia, potentiation of ethanol effects, and a tendency for tolerance and drug dependence.
GABA
A
selective ligands may also act to potentiate the effects of other CNS active compounds. For example, there is evidence that selective serotonin reuptake inhibitors (SSRIs) may show greater antidepressant activity when used in combination with GABA
A
selective ligands than when used alone.
SUMMARY OF THE INVENTION
This invention provides fused pyrroleoximes and pyrazoleoximes that bind, preferably with both high affinity and high selectivity, to the benzodiazepine site of the GABA
A
receptor, including human GABA
A
receptors.
Thus, the invention provides compounds of Formula I, and pharmaceutical compositions comprising compounds of Formula I.
The invention further comprises methods of treating patients suffering from CNS disorders with an effective amount of a compound of the invention. The patient may be a human or other mammal. Treatment of humans, domesticated companion animals (pet) or livestock animals suffering from CNS disorders with an effective amount of a compound of the invention is encompassed by the invention.
In a separate aspect, the invention provides a method of potentiating the actions of other CNS active compounds. This method comprises administering an effective amount of a compound of the invention with another CNS active compound.
Additionally this invention relates to the use of the compounds of the invention as probes for the localization of GABA
A
receptors in tissue sections.
Accordingly, a broad aspect of the invention is directed to compounds of Formula I
and the pharmaceutically acceptable salts thereof, wherein:
R is hydroxy, hydrocarbyl or —O-hydrocarbyl, where each hydrocarbyl is optionally substituted with oxo, haloalkyl, haloalkoxy, halogen, cyano, hydroxy, alkyl, nitro, azido, alkanoyl, carboxamido, alkoxy, aryloxy, alkylthio, alkylsulfinyl, alkylsulfonyl, amino, mono or dialkylamino, aryl, arylalkyl, arylalkoxy, heteroaryl or heterocycloalkyl; or
R is —O-aryl, aryl, —O-heteroaryl, or heteroaryl, each of which is optionally substituted with halogen, cyano, hydroxyl, nitro, azido, alkanoyl, carboxamido, hydrocarbyl, —O-hydrocarbyl, aryloxy, haloalkyl, haloalkoxy, hydrocarbylthio hydrocarbylsulfinyl, hydrocarbylsulfonyl, amino, mono or dihydrocarbylamino, aryl, arylhydrocarbyl, arylalkoxy, heteroaryl or heterocycloalkyl;
wherein each hydrocarbyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of oxo, halogen, cyano, nitro, haloalkyl, haloalkoxy, hydroxy, amino, alkyl substituted with 0-2 R
A
, alkoxy substituted with 0-2 R
A
, —NH(alkyl) substituted with 0-2 R
A
, —N(alkyl)(alkyl) where each alkyl is independently substituted with 0-2 R
A
, phenyl substituted with 0-3 R
A
, —XR
B
, and R
C
; wherein
R
A
is independently selected at each occurrence from the group consisting of halogen, hydroxy, alkyl, alkoxy, —NH(alkyl), —N(alkyl)(alkyl), heterocycloalkyl, —S(O)
m
(alkyl), where m is 0, 1, or 2, haloalkyl, haloalkoxy, —CO(alkyl), —CONH(alkyl), —CON (alkyl) (alkyl), —XR
B
, and Y;
X is independently selected at each occurrence from the group consisting of —CH
2
—, —CHR
C
—, —O—, —S(O)
g
—, —NH—, —NR
C
—, —C(═O)—, —C(═O)O—, —C(═O)NH—, —C(═O)NR
C
—, —S(O)
g
NH—, —S(O)
g
NR
C
—, NHC(═O)—, —NR
C
C(═O)—, —NHS(O)
g
—, and —NR
C
S(O)
g
—; where g is 0, 1, or 2;
R
B
and R
C
are independently hydrocarbyl which may be further substituted with one or more substituents independently selected from oxo, hydroxy, halogen, amino, —NH(alkyl), —N(alkyl)(alkyl), cyano, nitro, haloalkyl, haloalkoxy, —O(alkyl), —NHC(O)(alkyl), —N(alkyl)C(O)(alkyl), —NHS(O)
m
(alkyl), —S(O)
m
(alkyl), —S(O)
m
NH(alkyl), and —S(O)
m
N(alkyl)(alkyl); where each m is 0, 1, or 2;
Y is independently selected at each occurrence from 5- to 8-membered carbocycles or heterocycles, which are saturated, partially unsaturated, or aromatic and contain zero, one or two hetero atoms selected from N, O, and S, and which may be further substituted with one or more substituents independently selected from the group consisting of halogen, oxo, hydroxy, amino, mono- or di(C
1
-C
6
)alkylamino, nitro, cyano, C
1
-C
6
alkyl, C
1
-C
6
alkoxy, and —SO
a
(alkyl); where a is 0, 1, or 2;
R
1
and R
2
are independently selected at each occurrence from hydrogen, halogen, hydroxy, h

Affiliated with

Also associated with

Rating

Substituted fused pyrroleimines and pyrazoleimines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted fused pyrroleimines and pyrazoleimines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted fused pyrroleimines and pyrazoleimines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3346011